Hypothesis · not a trading signal
Q2 2026 · Published 2026-07-27 · Source checked 2026-09-06
- 01 / What the issuer reported
- Revenue was $1.584bn; backlog $8.1bn; RPO expected within twelve months was $4.2bn.
- 02 / Our hypothesis — not established alpha
- Design complexity and more custom chips can increase software value; AI productivity may also pressure seat-based pricing.
- 03 / What to measure next
- Organic recurring growth, renewal economics, RPO conversion, cash flow and stock-based compensation.
- 04 / What would challenge the thesis
- Reassess if AI usage grows without monetization, renewal pricing weakens or dilution offsets cash growth.
- 05 / Appropriate valuation method
- Recurring-software DCF with stock compensation and explicit multiple-compression stress.
- 06 / Still missing
- Missing: pricing/retention evidence and current price-implied duration of high growth.
No measured consensus gap or approved price target. A familiar good business can still be an expensive stock.